Do analysts rate IQV or ICLR?

IQVIA currently has a consensus target price of $264.31, suggesting a potential upside of 2.59%. Icon has a consensus target price of $172.40, suggesting a potential upside of 7.08%. Given Icon's higher probable upside, analysts clearly believe Icon is more favorable than IQVIA. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IQVIA 0 Sell rating(s) 3 Hold rating(s) 12 Buy rating(s) 2 Strong Buy rating(s) 2.94 Icon 2 Sell rating(s) 8 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.39

Which has preferable earnings & valuation, IQV or ICLR?

IQVIA has higher revenue and earnings than Icon. IQVIA is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IQVIA $16.31B 2.60 $1.36B $8.06 31.97 Icon $8.25B 1.49 $229.34M $4.26 37.80

Is IQV or ICLR more profitable?

IQVIA has a net margin of 8.10% compared to Icon's net margin of 3.99%. IQVIA's return on equity of 30.25% beat Icon's return on equity. Company Net Margins Return on Equity Return on Assets IQVIA 8.10% 30.25% 6.54% Icon 3.99% 8.02% 4.56%

Does the media refer more to IQV or ICLR?

In the previous week, IQVIA had 8 more articles in the media than Icon. MarketBeat recorded 11 mentions for IQVIA and 3 mentions for Icon. Icon's average media sentiment score of 1.00 beat IQVIA's score of 0.45 indicating that Icon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IQVIA 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Icon 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, MEDP or IQV?

IQVIA has higher revenue and earnings than Medpace. IQVIA is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medpace $2.53B 6.67 $451.12M $17.06 35.44 IQVIA $16.31B 2.60 $1.36B $8.06 31.97

Is MEDP or IQV more profitable?

Medpace has a net margin of 17.67% compared to IQVIA's net margin of 8.10%. Medpace's return on equity of 110.15% beat IQVIA's return on equity. Company Net Margins Return on Equity Return on Assets Medpace 17.67% 110.15% 24.84% IQVIA 8.10% 30.25% 6.54%

Does the media prefer MEDP or IQV?

In the previous week, Medpace had 19 more articles in the media than IQVIA. MarketBeat recorded 30 mentions for Medpace and 11 mentions for IQVIA. IQVIA's average media sentiment score of 0.45 beat Medpace's score of 0.36 indicating that IQVIA is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 11 Very Positive mention(s) 5 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral IQVIA 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, TECH or IQV?

IQVIA has higher revenue and earnings than Bio-Techne. IQVIA is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bio-Techne $1.22B 9.35 $181.86M $1.15 62.96 IQVIA $16.31B 2.60 $1.36B $8.06 31.97

Is TECH or IQV more profitable?

Bio-Techne has a net margin of 14.97% compared to IQVIA's net margin of 8.10%. IQVIA's return on equity of 30.25% beat Bio-Techne's return on equity. Company Net Margins Return on Equity Return on Assets Bio-Techne 14.97% 13.23% 10.61% IQVIA 8.10% 30.25% 6.54%

Does the media prefer TECH or IQV?

In the previous week, IQVIA had 7 more articles in the media than Bio-Techne. MarketBeat recorded 11 mentions for IQVIA and 4 mentions for Bio-Techne. IQVIA's average media sentiment score of 0.45 beat Bio-Techne's score of 0.07 indicating that IQVIA is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Techne 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral IQVIA 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor IQV or A?

In the previous week, Agilent Technologies had 1 more articles in the media than IQVIA. MarketBeat recorded 12 mentions for Agilent Technologies and 11 mentions for IQVIA. IQVIA's average media sentiment score of 0.45 beat Agilent Technologies' score of 0.29 indicating that IQVIA is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IQVIA 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Agilent Technologies 2 Very Positive mention(s) 0 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CRL or IQV?

In the previous week, Charles River Laboratories International and Charles River Laboratories International both had 11 articles in the media. Charles River Laboratories International's average media sentiment score of 0.91 beat IQVIA's score of 0.45 indicating that Charles River Laboratories International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Charles River Laboratories International 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IQVIA 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

IQVIA (IQV) Competitors

$258.48 -2.24 (-0.86%)

Closing price 03:59 PM Eastern

Extended Trading

$257.79 -0.69 (-0.27%)

As of 05:27 PM Eastern

Compare

IQV vs. ICLR, MEDP, TECH, A, and CRL

Should you buy IQVIA stock or one of its competitors? IQVIA's main competitors and comparable companies include Icon (ICLR), Medpace (MEDP), Bio-Techne (TECH), Agilent Technologies (A), and Charles River Laboratories International (CRL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does IQVIA compare to Icon?

IQVIA (NYSE:IQV) and Icon (NASDAQ:ICLR) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

89.6% of IQVIA shares are owned by institutional investors. Comparatively, 95.6% of Icon shares are owned by institutional investors. 1.7% of IQVIA shares are owned by insiders. Comparatively, 44.0% of Icon shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

IQVIA has a net margin of 8.10% compared to Icon's net margin of 3.99%. IQVIA's return on equity of 30.25% beat Icon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IQVIA	8.10%	30.25%	6.54%
Icon	3.99%	8.02%	4.56%

IQVIA has a beta of 1.17, meaning that its stock price is 17% more volatile than the broader market. Comparatively, Icon has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market.

In the previous week, IQVIA had 8 more articles in the media than Icon. MarketBeat recorded 11 mentions for IQVIA and 3 mentions for Icon. Icon's average media sentiment score of 1.00 beat IQVIA's score of 0.45 indicating that Icon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IQVIA	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Icon	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IQVIA currently has a consensus target price of $264.31, suggesting a potential upside of 2.59%. Icon has a consensus target price of $172.40, suggesting a potential upside of 7.08%. Given Icon's higher probable upside, analysts clearly believe Icon is more favorable than IQVIA.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IQVIA	0 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94
Icon	2 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.39

IQVIA has higher revenue and earnings than Icon. IQVIA is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IQVIA	$16.31B	2.60	$1.36B	$8.06	31.97
Icon	$8.25B	1.49	$229.34M	$4.26	37.80

Summary

IQVIA beats Icon on 11 of the 17 factors compared between the two stocks.

How does IQVIA compare to Medpace?

Medpace (NASDAQ:MEDP) and IQVIA (NYSE:IQV) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

IQVIA has higher revenue and earnings than Medpace. IQVIA is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53B	6.67	$451.12M	$17.06	35.44
IQVIA	$16.31B	2.60	$1.36B	$8.06	31.97

Medpace has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market. Comparatively, IQVIA has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market.

78.0% of Medpace shares are owned by institutional investors. Comparatively, 89.6% of IQVIA shares are owned by institutional investors. 20.5% of Medpace shares are owned by company insiders. Comparatively, 1.7% of IQVIA shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Medpace currently has a consensus price target of $602.27, suggesting a potential downside of 0.37%. IQVIA has a consensus price target of $264.31, suggesting a potential upside of 2.59%. Given IQVIA's stronger consensus rating and higher probable upside, analysts clearly believe IQVIA is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.23
IQVIA	0 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94

In the previous week, Medpace had 19 more articles in the media than IQVIA. MarketBeat recorded 30 mentions for Medpace and 11 mentions for IQVIA. IQVIA's average media sentiment score of 0.45 beat Medpace's score of 0.36 indicating that IQVIA is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	11 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
IQVIA	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Medpace has a net margin of 17.67% compared to IQVIA's net margin of 8.10%. Medpace's return on equity of 110.15% beat IQVIA's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.67%	110.15%	24.84%
IQVIA	8.10%	30.25%	6.54%

Summary

Medpace beats IQVIA on 9 of the 17 factors compared between the two stocks.

How does IQVIA compare to Bio-Techne?

Bio-Techne (NASDAQ:TECH) and IQVIA (NYSE:IQV) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Bio-Techne currently has a consensus price target of $68.92, indicating a potential downside of 4.81%. IQVIA has a consensus price target of $264.31, indicating a potential upside of 2.59%. Given IQVIA's stronger consensus rating and higher possible upside, analysts plainly believe IQVIA is more favorable than Bio-Techne.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	0 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.12
IQVIA	0 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94

IQVIA has higher revenue and earnings than Bio-Techne. IQVIA is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Techne	$1.22B	9.35	$181.86M	$1.15	62.96
IQVIA	$16.31B	2.60	$1.36B	$8.06	31.97

Bio-Techne has a beta of 1.3, meaning that its share price is 30% more volatile than the broader market. Comparatively, IQVIA has a beta of 1.17, meaning that its share price is 17% more volatile than the broader market.

In the previous week, IQVIA had 7 more articles in the media than Bio-Techne. MarketBeat recorded 11 mentions for IQVIA and 4 mentions for Bio-Techne. IQVIA's average media sentiment score of 0.45 beat Bio-Techne's score of 0.07 indicating that IQVIA is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Techne	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
IQVIA	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.0% of Bio-Techne shares are held by institutional investors. Comparatively, 89.6% of IQVIA shares are held by institutional investors. 1.3% of Bio-Techne shares are held by company insiders. Comparatively, 1.7% of IQVIA shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Bio-Techne has a net margin of 14.97% compared to IQVIA's net margin of 8.10%. IQVIA's return on equity of 30.25% beat Bio-Techne's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Techne	14.97%	13.23%	10.61%
IQVIA	8.10%	30.25%	6.54%

Summary

IQVIA beats Bio-Techne on 11 of the 17 factors compared between the two stocks.

How does IQVIA compare to Agilent Technologies?

IQVIA (NYSE:IQV) and Agilent Technologies (NYSE:A) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Agilent Technologies has a net margin of 19.53% compared to IQVIA's net margin of 8.10%. IQVIA's return on equity of 30.25% beat Agilent Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IQVIA	8.10%	30.25%	6.54%
Agilent Technologies	19.53%	24.45%	13.09%

IQVIA has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market. Comparatively, Agilent Technologies has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market.

IQVIA has higher revenue and earnings than Agilent Technologies. IQVIA is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IQVIA	$16.31B	2.60	$1.36B	$8.06	31.97
Agilent Technologies	$6.95B	6.79	$1.30B	$5.08	32.96

89.6% of IQVIA shares are owned by institutional investors. 1.7% of IQVIA shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

IQVIA presently has a consensus price target of $264.31, indicating a potential upside of 2.59%. Agilent Technologies has a consensus price target of $170.33, indicating a potential upside of 1.74%. Given IQVIA's stronger consensus rating and higher possible upside, analysts clearly believe IQVIA is more favorable than Agilent Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IQVIA	0 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94
Agilent Technologies	0 Sell rating(s)	5 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Agilent Technologies had 1 more articles in the media than IQVIA. MarketBeat recorded 12 mentions for Agilent Technologies and 11 mentions for IQVIA. IQVIA's average media sentiment score of 0.45 beat Agilent Technologies' score of 0.29 indicating that IQVIA is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IQVIA	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Agilent Technologies	2 Very Positive mention(s)	0 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

IQVIA beats Agilent Technologies on 10 of the 17 factors compared between the two stocks.

How does IQVIA compare to Charles River Laboratories International?

Charles River Laboratories International (NYSE:CRL) and IQVIA (NYSE:IQV) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

In the previous week, Charles River Laboratories International and Charles River Laboratories International both had 11 articles in the media. Charles River Laboratories International's average media sentiment score of 0.91 beat IQVIA's score of 0.45 indicating that Charles River Laboratories International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Charles River Laboratories International	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IQVIA	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Charles River Laboratories International currently has a consensus price target of $300.11, indicating a potential upside of 4.33%. IQVIA has a consensus price target of $264.31, indicating a potential upside of 2.59%. Given Charles River Laboratories International's higher probable upside, equities research analysts clearly believe Charles River Laboratories International is more favorable than IQVIA.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charles River Laboratories International	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82
IQVIA	0 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94

IQVIA has a net margin of 8.10% compared to Charles River Laboratories International's net margin of -5.96%. IQVIA's return on equity of 30.25% beat Charles River Laboratories International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charles River Laboratories International	-5.96%	15.75%	6.51%
IQVIA	8.10%	30.25%	6.54%

Charles River Laboratories International has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market. Comparatively, IQVIA has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market.

IQVIA has higher revenue and earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charles River Laboratories International	$4.02B	3.42	-$144.34M	-$4.85	N/A
IQVIA	$16.31B	2.60	$1.36B	$8.06	31.97

98.9% of Charles River Laboratories International shares are owned by institutional investors. Comparatively, 89.6% of IQVIA shares are owned by institutional investors. 1.3% of Charles River Laboratories International shares are owned by insiders. Comparatively, 1.7% of IQVIA shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

IQVIA beats Charles River Laboratories International on 10 of the 16 factors compared between the two stocks.

Get IQVIA News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IQV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IQV vs. The Competition

Export

Metric	IQVIA	Life Sciences Tools & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$42.55B	$10.67B	$7.11B	$22.72B
Dividend Yield	N/A	1.45%	2.53%	3.74%
P/E Ratio	32.07	75.03	274.42	27.75
Price / Sales	2.61	109.34	600.72	20.15
Price / Cash	15.05	27.76	77.38	39.56
Price / Book	6.64	6.85	10.92	4.64
Net Income	$1.36B	$57.48B	$3.50B	$1.08B
7 Day Performance	-4.31%	2.76%	-2.07%	-1.06%
1 Month Performance	-2.14%	7.78%	-6.32%	-5.02%
1 Year Performance	26.55%	35.62%	8.92%	5.78%

IQVIA Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IQV IQVIA	3.2784 of 5 stars	$258.48 -0.9%	$264.31 +2.3%	+27.7%	$42.55B	$16.31B	32.07	93,000	Analyst Forecast
ICLR Icon	3.3765 of 5 stars	$175.57 +1.9%	$170.07 -3.1%	-15.8%	$13.19B	$8.25B	41.21	40,100	Positive News Analyst Upgrade
MEDP Medpace	2.3641 of 5 stars	$615.94 -0.5%	$595.20 -3.4%	+10.0%	$17.27B	$2.53B	36.10	6,200	Trending News Analyst Upgrade Insider Trade
TECH Bio-Techne	2.7442 of 5 stars	$72.51 -0.1%	$68.92 -4.9%	+20.8%	$11.39B	$1.22B	63.05	3,000
A Agilent Technologies	4.2403 of 5 stars	$175.42 +1.5%	$170.33 -2.9%	+19.9%	$48.71B	$6.95B	34.53	18,100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:IQV) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IQVIA (IQV) Competitors